TBCRC 048:奥拉帕利治疗同源重组相关基因突变转移性乳腺癌的II期研究
该II期研究评估奥拉帕利对携带胚系非BRCA1/2同源重组相关基因突变(队列1)或体细胞BRCA1/2或这些基因突变(队列2)的转移性乳腺癌患者的疗效。确证缓解仅见于gPALB2(82%)和sBRCA1/2(50%)突变者,ATM或CHEK2突变 alone 无缓解。结论:PARP抑制对gPALB2或sBRCA1/2突变MBC有效,扩展了获益人群。
要点
- gPALB2突变者奥拉帕利客观缓解率达82%,中位PFS 13.3个月。
- sBRCA1/2突变者客观缓解率50%,中位PFS 6.3个月。
- ATM或CHEK2突变 alone 未见缓解,支持分子分型指导治疗。
核心结论
- PARP抑制对携带gPALB2或sBRCA1/2突变的转移性乳腺癌患者有效。
- 研究结果显著扩展了可能从PARP抑制剂获益的乳腺癌人群,超出gBRCA1/2突变携带者。
- 强调分子特征分析对转移性乳腺癌治疗决策的价值。
研究设计与样本
- 研究者发起的II期单臂两阶段研究(Olaparib Expanded)。
- 排除既往PARP抑制剂、铂难治或转移阶段超过两种化疗方案进展者;奥拉帕利300 mg口服每日两次至进展。
- 主要终点为客观缓解率,无效假设≤5%,若27例中≥4例缓解则拒绝;次要终点包括临床获益率和无进展生存期。
主要发现
- 队列1客观缓解率33%(90% CI 19%–51%),队列2为31%(90% CI 15%–49%)。
- 确证缓解仅见于gPALB2突变(客观缓解率82%)和sBRCA1/2突变(客观缓解率50%)。
- gPALB2突变者中位无进展生存期13.3个月(90% CI 12个月–不可计算),sBRCA1/2突变者为6.3个月(90% CI 4.4个月–不可计算)。
- ATM或CHEK2突变 alone 未观察到缓解。
关键数值与推荐
- 队列1客观缓解率33%(90% CI 19%–51%),队列2为31%(90% CI 15%–49%)。
- gPALB2突变客观缓解率82%,中位无进展生存期13.3个月(90% CI 12个月–不可计算)。
- sBRCA1/2突变客观缓解率50%,中位无进展生存期6.3个月(90% CI 4.4个月–不可计算)。
临床怎么用
- 对转移性乳腺癌患者进行分子检测,重点关注gPALB2和sBRCA1/2突变以指导PARP抑制剂使用。
- gPALB2或sBRCA1/2突变患者可考虑奥拉帕利治疗。
- ATM或CHEK2突变 alone 可能不足以作为奥拉帕利单药治疗的生物标志物。
局限性
- 单臂设计,无随机对照。
- 部分中位无进展生存期置信区间上限不可计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Olaparib Expanded, an investigator-initiated, phase II study, assessed olaparib response in patients with MBC with somatic (s)BRCA1/2 mutations or g/s mutations in homologous recombination (HR)-related genes other than BRCA1/2. METHODS: Eligible patients had MBC with measurable disease and germline mutations in non-BRCA1/2 HR-related genes (cohort 1) or somatic mutations in these genes or BRCA1/2 (cohort 2). Prior PARPi, platinum-refractory disease, or progression on more than two chemotherapy regimens (metastatic setting) was not allowed. Patients received olaparib 300 mg orally twice a day until progression. A single-arm, two-stage design was used. The primary endpoint was objective response rate (ORR); the null hypothesis (≤ 5% ORR) would be rejected within each cohort if there were four or more responses in 27 patients. Secondary endpoints included clinical benefit rate and progression-free survival (PFS). RESULTS: Fifty-four patients enrolled. Seventy-six percent had estrogen receptor-positive HER2-negative disease. Eighty-seven percent had mutations in PALB2, sBRCA1/2, ATM, or CHEK2. In cohort 1, ORR was 33% (90% CI, 19% to 51%) and in cohort 2, 31% (90% CI, 15% to 49%). Confirmed responses were seen only with gPALB2 (ORR, 82%) and sBRCA1/2 (ORR, 50%) mutations. Median PFS was 13.3 months (90% CI, 12 months to not available/computable [NA]) for gPALB2 and 6.3 months (90% CI, 4.4 months to NA) for sBRCA1/2 mutation carriers. No responses were observed with ATM or CHEK2 mutations alone. CONCLUSION: PARP inhibition is an effective treatment for patients with MBC and gPALB2 or sBRCA1/2 mutations, significantly expanding the population of patients with breast cancer likely to benefit from PARPi beyond gBRCA1/2 mutation carriers. These results emphasize the value of molecular characterization for treatment decisions in MBC.
引用
- Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020. PMID: 33119476. doi:10.1200/JCO.20.02151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。